| CODE | TYPE OF SERVICE | UOM |
| Outpatient Clinics (Codes 16, 19, 21) | ||
| 1 | First Consultation | /consultation |
| 2 | Follow-up Consultation | /consultation |
| 16/17 | Medical Report | /report |
| 21 | Dietician First Consultation | /consultation |
| 18 | Dietician Follow-Up Consultation | /consultation |
| 23/29 | Psychotherapy Consultation | /consultation |
| 19 | Genetic Counselling | /consultation |
| 41/42 | Speech Therapy Evaluation (private only) |
/evaluation |
| 43 | Speech Therapy Follow-up Appnt (private only) |
/consultation |
| 70/71 | Neuropsychologist Consultation(Private only) | /consultation |
| 72 | Neuropsychological Follow-up Consultation (Private only) | /evaluation |
| 27 | Copy of report (private only) | /copy |
| 31 | Copy of Medical File (private only) | /copy |
| Specialised Procedures | ||
| 32 | Peripheral blood smear and interpretation (private only) | /procedure |
| 33 | Flow cytometry interpretation, 2 to 8 markers (private only) | /procedure |
| Social Services (Code 21) | ||
| 21SO1 | Home visit | /hour |
| 21SO2 | Outpatient consultation |
/consultation |
| 21SO3 | Inpatient consultation |
/consultation |
| Physiotherapy (Code 24) | ||
| 1 | Home visit | /hour |
| 2 | Outpatients Treatment | /half hour |
| 3 | Inpatients Treatment | /half hour |
| 4 | Clinics | /half hour |
| 5 | Consultation | /half hour |
| 6 | Disabled living assessment | /hour |
| 9 | Clinical assessment | /hour |
| 10 | Group physiotherapy session (private only) | /45' |
| CODE | TYPE OF SERVICE | UOM |
| In Patient Ward (Code 20) | ||
| Day Care: | ||
| 3 | Accommodation & Nursing Care | /day |
| 20 | Medical Care | /day |
| 44 | Inpatient Speech Therapy Evaluation (Private only) |
/consultation |
| 50/51 | Inpatient Dietician Consultation |
/consultation |
| 73/74 |
Neuropsychological and psychological diagnostic investigation (private only) |
/investigation |
| 75/76 | Diagnostic Psychological tests (private only) | /investigation |
| 24 Hour Care: | ||
| 4 | 1st Class Accommodation & Nursing Care | /night |
| 5 | 2nd Class Accommodation & Nursing Care | /night |
| 6 | Medical Care | /night |
| 24 | Visiting Doctor | /consultation |
| 29 | Long Term Monitoring EEG (private only) | /night |
| Specialized Procedures: | ||
| 7 | Botulin Toxin Injections Generalised Dystonia | /procedure |
| 8 | Botulin Toxin Injections Segmental | /procedure |
| 9 | Tensilon Test | /procedure |
| 10 | Lumbar Puncture | /procedure |
| 25 | Sleep Study | /study |
| 26 | Minor surgical procedures | /procedure |
| CODE | TYPE OF SERVICE | UOM |
| 12 | Nerve conduction studies per limb | /limb |
| 13 | Blink Reflex | /test |
| 14.1 | Nerve conduction studies for more than two limbs | /session |
| 14.2 | EMG for more than two limbs | /session |
| 15 | Quantitative EMG | /test |
| 16 | Single fibre EMG | /test |
| 25 | Repetitive stimulation | /nerve |
| 26 | Mixed NCS | /nerve |
| 27 | Inching | /nerve |
| 28 | Sympathetic Skin Response | /test |
| 29 | H-reflex | /nerve |
| 31 | EMG per limb | /limb |
| 33 | Jaw Jerk Reflex | /session |
| 34 | Masseter Inhibitory Reflex | /session |
| 41 | Copy of report (private only) | /copy |
| CODE | TYPE OF SERVICE | UOM |
| 1 | Visual evoked potentials | /test |
| 3 | Flash visual evoked responses | /test |
| 4 | Pattern Electroretinogram | /test |
| 5 | Brainstem auditory evoked potentials | /test |
| 6 | Threshold Latency Series | /test |
| 7.1 | Upper limb somatosensory evoked potentials | /test |
| 7.2 | Lower limb somatosensory evoked potentials | /test |
| 7.3 | Dermatomal SSEP's | /test |
| 8 | Motor evoked potentials | /test |
| 9 | Multi modal evoked potentials | /session |
| 30 | Routine EEG | /test |
| 44 | Routine pediatric EEG | /test |
| 11 | Long Term Monitoring EEG | /night |
| 17 | Intra-operative monitoring | /hour |
| 35 | Vagus Nerve Stimulation | /test |
| 38 | Myogenic Vestibular Evoked Potentials | /test |
| 45 | Ocular Vestibular Evoked Myogenic Potentials (oVEMPs) (private only) | /test |
| 40 | Copy of report (Private only) | /copy |
| 42 | Visiting Doctor (Private only) | /consultation |
| CODE | TYPE OF SERVICE | UOM |
| 10 | Extracranial Cerebrovascular Examination (Carotid doppler) | /test |
| 11 | Transcranial doppler | /test |
| 12 | Carotid and transcranial doppler | both tests |
| 13 | Transcranial doppler monitoring | /test |
| 40 | Copy of report (private only) | /copy |
| CODE | TYPE OF SERVICE | UOM |
| MUSCLE BIOPSY: | ||
| 1 | Routine: H&E, Gomori, ATPase 9.4,4.6,4.3, SDH, NADH-TR, Cytochrome C, α-glycerophosphate, Oil Red O, PAS | /biopsy |
| 2 | Metabolic: Myophosphorylase, Phosphofructokinase, Adenylate deaminase | /biopsy |
| 3 | Inflammatory: MHC I, C5b9, Acid Phosphatase | /biopsy |
| 4 | Dystrophinopathy screen: Dys 3,1,2 Utrophin, spectrin | /biopsy |
| 5 | Dystrophy screen: α,β,γ,δ sarcoglycan, dysferlin, caveolin, merosin, α-dystroglycan, β-dystroglycan, collagen VI, spectrin | /biopsy |
| 7 | Paraffin: H&E Inflammatory, B & T cell, macrophage markers | /biopsy |
| 8 | Developmental: Desmin, Vimentin, Myosin, Utrophin | /biopsy |
| NERVE BIOPSY: | ||
| 9 | Paraffin: H&E, Congo Red | /biopsy |
| 11 | Immunocytochemistry (frozen) | /biopsy |
| 12 | Paraffin: H& E, B & T and macrophage markers | /biopsy |
| BRAIN EXAMINATION: | ||
| 13 | Whole brain examination | /biopsy |
| CODE | TYPE OF SERVICE | UOM |
| 1 | Prenatal diagnosis for Thalassaemia - 1st CVS | /prenatal |
| 2 | Prenatal diagnosis for Thalassaemia - 2nd CVS | /prenatal |
| 3 | Diagnostic samples for Thalassaemia | /sample/site |
| 4 | Alpha and beta locus MLPA analysis | /sample |
| 10 | Molecular Diagnosis for Thalassaemia | /sample |
| 13 | Sequencing of globin gene | /sample |
| 14 | DNA extraction from blood | /extraction |
| 15 | DNA extraction from tissue | /extraction |
| 16 | Pre-implantation genetic diagnosis (PGD) | /case |
| 17 | NIPD for X-linked disorders | /sample |
| 18 | Non Invasive prenatal diagnosis for fetal RHD status (private only) | /sample |
| 19 | Non invasive prenatal diagnosis for β-thalassaemia | /sample |
| 20 | Epo test (private only) | /sample |
| 21 | sTfR test (private only) | /sample |
| 22 | LIP test (private only) | /sample |
| 23 | NTBI test (private only) | /sample |
| 24 | Oxidative stress test (private only) | /sample |
| 25 | Modifiers of β-thalassaemia test (private only) | /sample |
| 26 | Targeted NGS panel for the molecular diagnosis of rare anaemias (RA-NGS) | |
| 27-30 | Targeted in silico gene panel | |
| 31/32 | Whole exome sequencing (WES) | |
| 33/34 | Clinical exome sequencing (CES) | |
| 35/36 | Open up of NGS data after in silico panel | /sample |
| 38 | Confirmation of SNVs with Sanger Sequencing (SNV-SANGER) | /sample |
| 39 | Trio in silico panel from WES ( applied for all above disease specific panels) | /family trio |
| 40 | Trio in silico panel from CES (applied for all above disease specific panels) | /family trio |
| CODE | TYPE OF SERVICE | UOM |
| FORENSIC GENETICS | ||
| 5.1* | DNA Profiling of one person |
/person |
| 5.2* |
Duo or Trio Kinship test |
/case |
| 5.3* |
Each additional person to be included in Duo or Trio kinship test |
/person |
| 5.4* | Kinship with one skeletal element | /element |
| 5.5* | Kinship test with each additional skeletal element | /element |
| 6 | Other forensic genetic services (police) | /case |
| 12 | Other forensic genetic services (missing persons) | /case |
| CARDIOVASCULAR GENETICS | ||
| 3 | Familial Hypercholesterolaemia | /family |
| 4 | Apolipoprotein E Genotyping | /case |
| 9 | Thrombophilia (4 mutations simultaneously) | /case |
| 11 | Cardio panel (in silico panel from CES/WES) | /case |
| 15/16 | Clinical Exome Sequencing | /patient/trio |
| 17/18 | Whole Exome Sequencing | /patient/trio |
| 19 | Sanger sequencing for confirmation/screening of NGS result | /case |
| SCREENING FOR MITOCHONDRIAL MUTATIONS | ||
| 13 | Molecular Investigation of MItochondrial Diabetes and Deafness (MIDD) | /case |
| * plus VAT |
| CODE | TYPE OF SERVICE | UOM |
| CYSTIC FIBROSIS (CF) | ||
| 1.1 | CF full mutation analysis (by NGS) | /test |
| 1.6 | CF DNA extraction/storage | /extraction |
| HEREDITARY RECURRENT FEVERS | ||
| Familial Mediterranean Fever (FMF): | ||
| 7.1 | FMF full mutation analysis (sequencing) | /test |
| 7.2 | FMF analysis for known mutation (sequencing) | /test |
| 7.6 | FMF DNA extraction/storage | /extraction |
| Cryopyrin-associated periodic syndrome) – CAPS: | ||
| 24.3 |
Hereditary recurrent fevers (HRF) (in silico panel from WES) |
/test |
| SWEAT TEST | ||
| 8.7 | Sweat test | /test |
| HAEMOCHROMATOSIS | ||
| 10.7 | Haemochromatosis analysis of individual mutations | /test |
| RET - PROTO-ONCOGENE | ||
| 11.1 | RET full mutation analysis (sequencing) | /test |
| 11.2 | RET analysis for known mutation (sequencing) | /test |
| 11.6 | RET DNA extraction/storage | /extraction |
| INHERITED DEAFNESS | ||
| Hearing Loss, Gap Junction Beta 2 & 6 genes: | ||
| 13.1 | Connexin 26 (GJB2) full mutation analysis (sequencing) | /test |
| 13.2 | Connexin 26 analysis for known mutation (sequencing) | /test |
| 13.6 | Connexin DNA extraction/storage | /extraction |
| 15.1 | Connexin 30 (GJB6) full mutation analysis (sequencing) | /test |
| 15.2 | Connexin 30 analysis for known mutation (sequencing) | /test |
| 15.6 | Hearing Loss (in silico ppanel from WES) | /test |
| MULTIPLE SCLEROSIS | ||
| 14 | Oligoclonal Bands detection for MS patients | /test |
| CONGENITAL ADRENAL HYPERPLASIA - CAH | ||
| CYP21A2 gene analysis: | ||
| 16.1 | CYP21A2 gene full mutation analysis (sequencing) | /test |
| 16.2 | CYP21A2 gene analysis for known mutation (sequencing) | /test |
| 16.6 | Congenital Adrenal Hyperplasia DNA extraction/storage | /extraction |
| 16.7 | Congenital Adrenal Hyperplasia Sequencing per test (exon sequencing) | /test |
| OBESITY | ||
| 17.1 | MC4R full sequencing | /test |
| 17.2 | Obesity analysis for known mutation | /test |
| 17.6 | Obesity DNA extraction/storage | /extraction |
| MATURITY ONSET DIABETES OF THE YOUNG (MODY) | ||
| HNF1a gene (MODY 3): | ||
| 20.7 |
Glucose and Insulin Homeostasis (MODY and OBESITY) (in silico panel from WES) |
/test |
| DISORDERS OF SEXUAL DIFFERENTIATION - DSD | ||
| 45 |
Disorders of Sexual Development (CAH and DSDs) (in silico panel from WES) |
/test |
| 5-alpha reductase deficiency: | ||
| 21.1 | SRD5A2 Full Mutation Analysis (sequencing) (private only) | /test |
| 21.2 | SRD5A2 Analysis of Known Mutation (sequencing) (private only) | /test |
| GROWTH HORMONE DEFICIENCY | ||
| CENTRAL PRECOCIOUS PUBERTY (CPP) | ||
| 38.1 | MKRN3 gene full mutation analysis (private only) | /test |
| 38.2 | MKRN3 gene known mutation analysis (private only) | /test |
| 38.4 | Premature and Delayed Puberty (in silico panel from WES) | /test |
| THYROID FUNCTION | ||
| 39.1 | Thyroid Function (in silico panel from WES) | /test |
| EXOME SEQUENCING | ||
| 41/42 | Clinical Exome Sequencing-CES | |
| 43/44 | Whole Exome Sequencing-WES | |
| 46 | Sanger sequencing based confirmation of a variant identified by NGS | /test |
| OTHER | ||
| 96 | Other DNA extraction/storage | /extraction |
| CODE | TYPE OF SERVICE | UOM | |
| 1 | Transthyretin Val30Met mutation detection test | /patient | |
| 1.01 | Transthyretin DNA sequencing test | /patient | |
| 2 | Huntington CAG triplet repeat test | /patient | |
| 3 | Friedreich’s Ataxia (FRDA) Frataxin GAA tiplet repeat test | /patient | |
| 3.01 | National Prevention Program for Friedreich Ataxia | /test | |
| 4 | Spinocerebellar Ataxia 1 (SCA1) CAG triplet repeat test | /patient | |
| 5 | Spinocerebellar Ataxia 3 (SCA3) CAG triplet repeat test | /patient | |
| 6.02 | Myelin Protein Zero (MPZ) sequencing test | /test | |
| 6.03 | Connexin 32 (CX32 / GJB1) sequencing test | /test | |
| 6.04 | Peripheral Myelin Protein 22 (PMP22) sequencing test | /test | |
| 6.05 | CMT1A/HNPP MLPA evaluation | /test | |
| 6.06 | Mitofusin 2 (MFN2) gene sequencing test | /test | |
| 6.07 | Neurofilament-light (NEFL) gene sequencing test | /test | |
| 6.08 | Ganglioside-induced differentiation-associated protein 1 (GDAP1) gene sequencing test | /test | |
| 6.09 | Glycyl-tRNA synthetase (GARS) gene sequencing test [CMT2D; DSMAV] | /test | |
| 6.1 | Early growth response 2 (EGR2) gene sequencing test [CMT1D; CMT4E] | /test | |
| 6.11 | Detection of the c.892C>T mutation in exon 5 of the LMNA gene [ARCMT2] | /test | |
| 7.01 | SMA MLPA evaluation | /patient | |
| 8 | Known LGMD2 mutation detection test | /patient | |
| 8.01 | Linkage analysis (LGMD2A – LGMD2I loci) | /family | |
| 9 | DM1 CTG triplet repeat test | /patient | |
| 10 | DNA Extraction & Banking | /patient | |
| 12/13/14 | Spinocerebellar Ataxia 2/6/7 (SCA2/6/7) CAG triplet repeat test | /patient | |
| 15 | SCA Panel (SCA1, 2, 3, 6, 7) test | /patient | |
| 16/17/18 | Spinocerebellar Ataxia 8/17/18 (SCA8/17/18) CTA/CTG repeat test | /patient | |
| 19 | DRPLA CAG triplet repeat test | /patient | |
| 20 | Aprataxin (APTX) sequencing test | /patient | |
| 21 | Spinocerebellar Ataxia 10 (SCA10) ATTCT repeat test | /patient | |
| 22 | Spinal and bulbar muscular atrophy (SBMA) or Kennedy’s disease, androgen receptor CAG triplet repeat test | /patient | |
| 23 | SOD1 gene sequencing test | /patient | |
| 24 | Detection of the N88S / S90L mutations in exon 3 of the BSCL2 gene [HMN5] | /test | |
| 25 | TAR DNA binding protein TARDBP (TDP-43) gene sequencing test [ALS10] | /test | |
| 26 | Detection of the G2019S mutation in exon 41 of the LRRK2 gene [PARK8] | /test | |
| 27 | Gap junction protein, gamma 2 (GJC2) gene sequencing test [SPG44] | /test | |
| 28 | Spastin (SPAST) gene sequencing test [SPG4] | /test | |
| 29 | Atlastin GTPase 1 (ATL1) gene sequencing test [SPG3] | /test | |
| 30 | SPAST and ATL1 genes MLPA evaluation [SPG4 and SPG3] | /test | |
| 31 | Receptor expression enhancing protein 1 (REEP1) gene sequencing test [SPG31] (private only) | /test | |
| 32 | Fused in sarcoma (FUS) gene sequencing test [ALS6] (private only) | /test | |
| 33 | C9orf72 gene GGGGCC hexanucleotide repeat test [ALSFTD] (private only) | /test | |
| 34 | Lamin A/C (LMNA) gene sequencing test [CMD1A] (private only) | /test | |
| 35 | ATPase, Na+/K+ transporting, alpha 2 polypeptide (ATP1A2) gene sequencing test [FHM2] (private only) | /test | |
| 36 | Low density lipoprotein receptor-related protein 5 (LRP5)(private only) | /test | |
| 37 |
|
/family | |
| 40.2 |
Cardiomyopathy panel (in silico panel from WES) |
/patient | |
| 41 | Amyotrophic Lateral Sclerosis panel (in silico panel from WES) | /patient | |
| 42 | Ataxia panel (in silico panel from WES) | /patient | |
| 43 |
Cerebral Cavernous Malformation panel (in silico panel from WES) |
/patient | |
| 44 |
Charcot-Marie-Tooth Neuropathy panel (in silico panel from WES) |
/patient | |
| 45 |
Congenital Myasthenic Syndromes panel (in silico panel from WES) |
/patient | |
| 46 |
Custom Neuro panel (in silico panel from WES) |
/patient | |
| 47 |
Dementia panel (in silico panel from WES) |
/patient | |
| 48 |
Distal Hereditary Motor Neuropathy panel (in silico panel from WES) |
/patient | |
| 49 |
Dystonia panel (in silico panel from WES) |
/patient | |
| 50 |
Epilepsy panel (in silico panel from WES) |
/patient | |
| 51 |
Hemiplegia/Stroke Panel (in silico panel from WES) |
/patient | |
| 52 |
Leukodystrophy and Leukoencephalopathy panel (in silico panel from WES) |
/patient | |
| 53 |
Migraine panel (in silico panel from WES) |
/patient | |
| 54 |
Muscular Dystrophy-Myopathy panel (in silico panel from WES) |
/patient | |
| 55 |
Neurofibromatosis panel (in silico panel from WES) |
/patient | |
| 56 |
Neuro-ophthalmic panel (in silico panel from WES) |
/patient | |
| 57 |
Parkinson Disease panel (in silico panel from WES) |
/patient | |
| 58 |
Retinal degeneration panel (in silico panel from WES) |
/patient | |
| 59 |
Spastic Paraplegia panel (in silico panel from WES) |
/patient | |
| 60 |
Spinal Muscular Atrophy panel (in silico panel from WES) |
/patient | |
| 61 |
Tuberous Sclerosis panel (in silico panel from WES) |
/patient | |
| 64/65 | Whole Exome Sequencing-WES (Single/Trio) | /patient | |
| 67 |
Open WES data after in silico panel |
/patient | |
| 69 |
Trio in silico panel from WES (applied for all above disease specific panels) |
/family trio | |
| 70 | Sanger sequencing based confirmation of a variant identified by NGS | /patient | |
| 71 | Carrier diagnosis for Duchenne | /test | |
| 72 | RFC1 gene AAGGG pentanucleotide repeat test [CANVAS and other RFC1-related disorders] | /test | |
| 73 | FGF14 gene GAA triplet repeat expansion test [SCA27B] | /test | |
| 80 | Family Analysis* |
/family |
|
| 81/82 | Prenatal diagnosis* | /prenatal | |
| 83 | Analysis of known gene mutation for additional family members | /test | |
| *Provided for all diseases specified above |
| CODE | TYPE OF SERVICE | UOM |
| 1 | Chromosomal analysis of CVS - Prenatal Diagnosis | /test |
| 2 | Chromosomal analysis of Amniotic Fluid | /test |
| 3 | Chromosomal analysis of Fetal Blood | /test |
| 4 | Chromosomal analysis of Peripheral Blood | /test |
| 5 | Chromosomal analysis of Skin Biopsy | /test |
| 6 | Examination and chromosomal analysis of Prod. of Conception (POC) | /test |
| 7 | Tissue Culture Only - To facilitate other tests | /specimen |
| 8 | Chromosomal analysis of Peripheral Blood for couples | /test |
| 20 | Identification/Confirmation/Characterisation of Chromosomal abnormality(ies) by FISH | /test |
| 21 | Diagnosis of Disease(s) / Syndrome(s) by FISH | /test |
| 22 | Multiprobe detection centromeric/telomeric | /test |
| 23 | Pre-implantation Genetic Diagnosis by FISH | /test |
| 24 | M-FISH | /test |
| 25 | Sperm FISH for chromosome aneuploidies analysis | /test |
| 26 | Sperm DNA fragmentation analysis |
/test |
| 27 | Sperm Oxidative Stress (private only) | /test |
| 60 | Prenatal diagnosis of Fragile X Syndrome | /family |
| 61 | Postnatal diagnosis of Fragile X Syndrome/per Individual | /test |
| 62 | Investigation of abnormalities/syndromes with MLPA or qRT PCR/PCR | /person |
| 63 | DNA Isolation/storage | /sample |
| 64 | Detection of Y chromosomal material/ per individual | /sample |
| 65 | Screening of Y(AZF) chromosomal microdeletions | /sample |
| 66 | Achondroplasia mutation G1138A analysis | /sample |
| 67 | Central Diabetes Insipidus | /sample |
| 68 | Molecular diagnosis of Prader Willi/Angelman syndrome | /test |
| 69 | Rapid prenatal diagnosis of 13,18,21,X,Y aneuploides (QF-PCR) | /test |
| 70 | Detection of genomic imbalances with microarray-CGH | /sample |
| 71 | Pre-implantation Genetic Testing with array CGH or NGS | /sample |
| 80 | Establish Lymphoblastoid Cell Line | /sample |
| 81 | Establish Fibroblast Cell Line | /sample |
| 82 | Thawing-Freezing-Expansion up to 2T-25 Flasks | /sample |
| 83 | Maintain Two Vials/Sample in N2/year | /sample |
| 110 | Targeted Panel up to 50 genes | /test |
| 111 | Clinical Exome Sequencing (Single patient analysis) | /test |
| 112 | Clinical Exome Sequencing (Trio analysis) | /family trio |
| 113 | In Silico Panel from Clinical Exome Sequencing (Single Patient analysis) | /test |
| 114 | In Silico Panel from Clinical Exome Sequencing (Trio analysis) | /family trio |
| 115 | Whole Exome Sequencing (Single patient analysis) | /test |
| 116 | Whole Exome Sequencing (Trio analysis) | /family trio |
| 117 | Open up the CES data after in silico panel | /test |
| 118 | Open up the WES data after in silico panel | /test |
| 119 | Sanger DNA sequencing for confirmation of mutation/variant detected by NGS/patient | /test |
| CODE | TYPE OF SERVICE | UOM |
| BIOCHEMICAL ASSAYS | ||
| 1 | Lactate | /test |
| 2 | Pyruvate | /test |
| 4 | Ischaemic Exercise Test | /test |
| 5 | Ammonia | /test |
| 7 | Creatine Kinase | /test |
| 8 | Creatine Kinase Isoenzymes | /test |
| 9 | Amino Acids (Plasma/Urine/CSF) | /test |
| 10 | Acylcarnitines | /test |
| 12 | Vitamin E | /test |
| 13 | Urine Screen (Stick) | /test |
| 14 | Urine Spot Tests | /test |
| 14.1 | Reducing Substances | /test |
| 14.2 | Nitroprusside test for Cystine/Homocystine | /test |
| 15 | Biotinidase | /test |
| 16 | Hexosaminidase A & B | /test |
| 17 | Lysosomal Enzymes Single | /test |
| 18 | Lysosomal Enzymes Screen | /test |
| 19 | Mucopolysaccharides (GAG/creatine ratio) | /test |
| 21 | Mucopolysaccharides (GAG Electrophoresis) | /test |
| 24 | C26:0-LysoPC in plasma (private only) | /test |
| 31 | Organic Acids | /test |
| 31.2 | Plasma methylmalonic acid | /test |
| 32.1 | DNA Isolation | /extraction |
| 32.3/32.4 | Metabolic Disorders in silico panel from CES Single/Trio | /test /family trio |
| 32.5 | Open up CES data after in silico panel | /test |
| 32.6/32.7 | Metabolic Disorders WES Single/Trio |
/test |
| 32.8 | Sanger sequencing for confirmation of NGS result | /test |
| 65 | Total Homocysteine | /test |
| 66 | Sugar Chromatography (TLC) | /test |
| 67 | Oligosaccharides (TLC) | /test |
| 69 | Vitamin B12 | /test |
| 70 | Folate | /test |
| 71 | Homocysteine - B12 - Folate screen | /test |
| 80 | Vitamins A&E | /test |
| 81 | Vitamin A | /test |
| 82 | Viramin D | /test |
| MUSCLE BIOCHEMISTRY | ||
| 40 | Carnitine Palmitoyl Transferase | /test |
| 41 | Mitochondrial Enzymes | /test |
| 42 | Muscle enzymes single | /test |
| 46 | Dystrophin | /test |
| 47 |
Dysferlin WB (private only) |
/test |
| 49 | Calpain WB (private only) | /test |
| 50 |
Dysferlin & Caplain WB (private only) |
/test |
| CODE | TYPE OF SERVICE | UOM | |
| 1 | Processing and examination of specimens in the TEM | /test | |
| 2 | Examination of specimens in the TEM | /test | |
| 3/4 | Use of TEM per session | /session | |
| 5 | Consultation test for cancer susceptibility | /consultation | |
| 6/7 | DNA extraction/storage from blood/tissue | /extraction | |
| 8/9 | mRNA extraction/storage from tissue/blood | /extraction | |
| 10/12 | BRCA1/BRCA2 mutation screen | /test | |
| 11/13 | BRCA1/BRCA2 analysis for known mutation | /test | |
| 14/16 | p53/APC mutation screen | /test | |
| 15/17 | p53/APC analysis for known mutation | /test | |
| 18 | Microsattelite instability (MSI) | /test | |
| 19/21 | MLH1/hMLH2/MLH6 mutation screen | /test | |
| 20/22 | MLH1/MLH2 analysis for known mutation | /test | |
| 23/25 | PMS1/PMS2 mutation screen | /test | |
| 24/26 | PMS1/PMS2 analysis for known mutation | /test | |
| 27 | MSH6 mutation screen | /test | |
| 28 | MSH6 analysis for known mutation | /test | |
| 29 | K-ras mutation detection | /test | |
| 29.1 | K-ras somatic mutation detection | /test | |
| 29.2 | K-ras/N-ras somatic mutation detection (private only) | /test | |
| 30/31/32 | Immunohistochemistry of MLH1/MLH2/MLH6 | /test | |
| 33 | Immunohistochemistry of PMS2 | /test | |
| 41/43/45 | PTEN/STK11/CHEK 2 mutation screen | /test | |
| 42/44/46 | PTEN/STK11/CHEK 2 analysis for known mutation | /test | |
| 47/49/51 | ATM/PALB2/BRIP1 mutation screen | /test | |
| 48/50/52 | ATM//PALB2/BRIP1 analysis for known mutation | /test | |
| 53/55 | CDKN2A/BRAF mutation screen | /test | |
| 54/56 | CDKN2A/BRAF analysis for known mutation | /test | |
| 57 | Mitochondrial DNA sequencing for a single gene | /test | |
| 58 | Mitochondrial DNA analysis for known mutation | /test | |
| 59 | Mitochondrial DNA southern blot for detection of multiple deletion(s), duplication(s) and depletion | /test | |
| 60 | Mitochondrial DNA mutation Screen | /test | |
| 61 | EGFR full gene testing | /test | |
| 62 | EGFR exons 18-21 testing | /test | |
| 62.1 | EGFR T790 mutation detection in circulating cell-free tumour DNA (private only) | /test | |
| 63 | CFHR5 Nephropathy (private only) | /test | |
| 64 | KIT mutation screen (private only) | /test | |
| 65 | KIT analysis for exons 9,11,13,17 (private only) | /test | |
| 66 | KIT analysis of known mutation (private only) | /test | |
| 67 | PDGFRA mutation screen (private only) | /test | |
| 68 | PDGFRA analysis of exons 12,18 (private only) | /test | |
| 69 | PDGFRA analysis for known mutation (private only) | /test | |
| 70 | CDH1 mutation screen (private only) | /test | |
| 71 | CDH1 analysis for known mutation (private only) | /test | |
| 72/74 | MUTYH/VHL mutation screen (private only) | /test | |
| 73/75 | MUTYH/VHL analysis for known mutation (private only) | /test | |
| Discovery proteomics LC-MS/MS: Platform 1, Synapt G2Si – nanoAcquity: | |||
| 76 | 1D nanoLC-MS/MS 220 min gradient (private only) | /sample | |
| 77 | 2D (RP-RP) nanoLC-MS/MS, 6 fractions, 150min gradient/fraction (private only) | /sample | |
| 78 | Data analysis (Proteomics) (private only) | per set of data deriving from the analysis of 10-15 samples | |
| Targeted analysis LC-MRM: Platform 2, Xevo TQD-Acquity UPLC: | |||
| 79 | Method development (private only) | ||
| 80 | Price per sample for pre-developed MRM assay (private only) | ||
| 81 |
BRCA1/2 somatic mutation detection by NGS |
/test | |
| 82 | Mitochondrial nuclear gene panel by NGS >100 genes | /test | |
| 83 | Mitochondrial nuclear gene panel by NGS >100 genes | /test | |
| 84 | Hereditary breast and ovarian cancer NGS panel 23 |
|
|
| 85 | Hereditary colon cancer NGS panel 21 genes |
|
|
| 86 | Comprehensive hereditary cancer NGS panel 37 genes |
|
|
| 87 | NGS panel for primary cilliary diskinisia 33 genes |
|
|
| 88 | Somatic hotspot cancer panel for selection of targeted therapies |
|
|
| 89 | RNA lung cancer panel (fusions, translocations) |
|
|
| 90/90.1 | Whole Exome Sequencing-WES | /test /family trio |
|
| 91 | Sanger sequencing for confirmation of NGS result | /test |
|
CODE |
TYPE OF SERVICE |
UOM |
|
3/4 |
CMV-IgG/IgM | /test |
|
17/18 |
Toxoplasma IgG/IgM |
/test |
|
HEPATITIS-RELATED |
||
|
41 |
Hepatitis: HBV - DNA |
/test |
|
42 |
Hepatitis: HCV - RNA |
/test |
|
HERPESVIRUSES |
||
| 43 |
Herpesvirus: CMV - DNA |
/test |
| 44 |
Herpesvirus: HSV1 - DNA |
/test |
| 45 |
Herpesvirus: HSV2 - DNA |
/test |
| 46 |
Herpesvirus: EBV - DNA |
/test |
| 47 |
Herpesvirus: VZV- DNA |
/test |
| 73/74/75 |
PCR HHV6/7/8-DNA |
/test |
|
HUMAN PAPILLOMA VIRUSES |
||
| 49.1 |
Human Papilloma Viruses - DNA (standard request) |
/test |
| 51 | High-Risk Human Papillomaviruses (HPV) E6/E7 mRNA Detection Assay (private only) | /test |
|
OTHER VIRUSES |
||
| 48 |
RT/PCR Polio, Coxsaxkie, Echo, Entero - Virus |
/test |
| 63 |
Adenoviruses : Adeno - DNA |
/test |
| 71 |
PCR Parvovirus-DNA |
/test |
| 78 |
Toxoplasma DNA |
/test |
|
MENINGITIS-RELATED |
||
| 83 |
Neisseria meningitidis (private only) |
/test |
| 84 |
Listeria Monocytogenes (private only) |
/test |
| 85 |
Streptococcus pneumoniae (private only) |
/test |
| 86 |
Haemophilus influenza b (private only) |
/test |
| 87 |
Panel: N. meningitidis, S. pneumoniae, H. influenzae (private only) |
/test |
|
PNEUMONIA-RELATED |
||
| 88 |
Chlamydia pneumoniae (private only) |
/test |
| 89 |
Mycoplasma pneumoniae (private only) |
/test |
|
HIV |
||
|
91 |
HIV-1 RNA (private only) |
/test |
|
92 |
HIV-1 Drug resistance typing (private only) |
/test |
| MALARIA | ||
| 93 |
Plasmodium spp. (private only) |
/test |
| ZOONOTIC DISEASES | ||
| 94 |
Coxsiella burnetti (private only) |
/test |
| 95 |
Anaplasma spp. (private only) |
/test |
| 96 |
Rickettsia typhi (private only) |
/test |
| 97 |
Leishmania spp. (private only) |
/test |
|
RESPIRATORY VIRUSES |
||
| 77 |
Influenza virus A(H1N1) (Swine) - rRT-PCR |
/test |
| 81/82 |
Respiratory Viruses Panel |
/test |
| 110 |
MERS Coronavirus (private only) |
/test |
| 111 |
Influenza A Typing (private only) |
/test |
| 123 | SARS-CoV-2 (2019-nCoV) (private only) | /test |
|
GASTROINTESTINAL VIRUSES |
||
| 67 |
RT/PCR - Rotavirus |
/test |
| 72 |
RT-PCR Norovirus-RNA |
/test |
| 112 |
Astrovirus (private only) |
/test |
| 113 |
Panel: Rotavirus, Norovirus, Astrovirus, Adenovirus (private only) |
/test |
|
VECTORBORNE VIRUSES |
||
| 79 |
Phleboviruses |
/test |
| 80 | Flaviviruses | /test |
| 80.1 |
Zikavirus (private only) |
/test |
| 114 |
Alphaviruses (Chikungunya virus, O’Nyong Nyong virus, etc.) (private only) |
/test |
| 115 |
Ebolavirus and other haemorraghic fever viruses (private only) |
/test |
| 116 |
Crimean–Congo hemorrhagic fever (private only) |
/test |
|
PATHOGEN SEQUENCING |
||
| 52 | 16S rRNA Metagenomic Bacterial Identification Assay (private only) | /test |
|
OUTBREAK INVESTIGATION |
||
|
117 |
Investigation of outbreaks caused by infectious pathogens (private only) |
/test |
|
CODE |
TYPE OF SERVICE |
UOM |
|
ANIMAL CAGE MAINTENANCE |
||
|
1/2 |
Small / Large cage maintenance |
/week |
| 3 |
Metabolic cage maintenance |
/cage/use |
| 11 |
Small cage maintenance - CD1 nude / Nod-Scid mice / Filter Top |
/cage/week |
| 12 | Large cage maintenance - CD1 nude mice | /week |
| ANIMAL REQUEST | ||
| 4 | Non-stock lines |
/case |
| 4.01 | Rosa 26 R mice | /mouse |
| 4.02 |
C57BL6/6J mice |
/mouse |
|
4.03 |
BALBC mice |
/mouse |
|
4.05 |
CD1 mice |
/mouse |
|
4.12 |
Nod-Scid mice | /mouse |
|
4.13 |
SJL mice | /mouse |
|
4.2 |
CD1 nude mice | /mouse |
|
17 |
Foster mother (CD1 female) | /mouse |
| 19 |
Pseudopregnant female (CD1 or F1) |
/mouse |
|
BIOPSY AND GENOTYPING |
||
| 4.06 | Tail biopsy | /mouse |
| 4.07 | Tail biopsy and genotyping (LacZ) | /mouse |
| 4.08 | Tail biopsy and genotyping (DNA extraction + PCR) | /mouse |
| 4.09 | Embryo biopsy |
/embryo |
|
4.1 |
Embryo biopsy and genotyping (LacZ) |
/embryo |
|
4.11 |
Embryo biopsy and genotyping (DNA extraction + PCR) | /embryo |
| SPECIAL PROCEDURES | ||
| 18 |
Caesarean section (hysterectomy) |
/section |
| 20 |
Embryo transfer |
/transfer |
| 21 |
Superovulation of females and embryo collection |
/mouse |
| 22 |
Vasectomy of males (including the cost of mouse) |
/mouse |
|
TRANSGENIC SERVICE |
||
|
5.01/5.02 |
Blastocyst injection and chimera breeding package |
/package |
|
6.01/6.02 |
ES electroporation package |
/package |
|
14.01/14.02 |
Pronuclear injection package (incl. BAC injection) |
/package |
| PURIFICATION OF DNA | ||
|
15.01/15.02 |
DNA purification for BAC and 20 Kb |
/purification |
|
16.01/16.02 |
DNA purification for 20 Kb>constructs |
/purification |
| PACKAGING AND SHIPMENT OF MICE | ||
|
13 |
Delivery of live mice by messenger (Nicosia) |
/delivery |
|
23 |
Packaging of mice for export (including preparation of relevant documents) |
/cage |
| OTHER SERVICES | ||
|
10 |
Special service request |
/service |